The Global Arthritic Therapeutic Market is valued at approximately USD 83.87 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.5% over the forecast period 2024-2032. Arthritic therapeutics encompass a range of medical treatments designed to manage different types of arthritis, including rheumatoid arthritis and osteoarthritis. These treatments, which include NSAIDs, biologics, and advanced therapies, aim to enhance the quality of life for individuals by alleviating pain, reducing inflammation, and improving joint function. The growing geriatric population significantly drives the expansion of the arthritic therapeutic market. According to the World Health Organization (WHO), the global elderly population is expected to reach 1.4 billion by 2030, increasing the prevalence of arthritis. Consequently, the pharmaceutical industry is channeling efforts into developing various therapeutic solutions, including medications, biologics, and innovative treatments, to address this surge.

The market for arthritic therapeutics is experiencing robust growth, primarily driven by the rising prevalence of arthritis conditions, . As the number of diagnosed cases continues to rise, the demand for diverse therapeutics, including NSAIDs, biologics, and lifestyle modifications, grows, driving the continuous expansion of the arthritic therapeutic market. Moreover, the global focus on upgrading healthcare infrastructure is a crucial driver of arthritic therapeutic market growth. Enhanced healthcare infrastructure facilitates easier diagnosis, treatment, and management of arthritic conditions. This includes the establishment of specialized clinics, diagnostic facilities, and increased availability of arthritic therapies. Improved infrastructure not only enables prompt and accurate illness detection but also simplifies the administration of innovative and tailored medicines, supporting market growth. As healthcare systems advance, patients benefit from more efficient and comprehensive arthritis care, fueling market growth. This initiative aligns with the broader goal of addressing the rising prevalence of arthritis and improving overall public health outcomes. However, the arthritic therapeutic market faces challenges such as the availability of alternative and complementary therapies and the issue of insufficient diagnosis. Some individuals opt for non-conventional methods like acupuncture, herbal medicines, and dietary interventions instead of traditional medical treatments, impacting market growth. Additionally, lack of awareness and inadequate diagnosis delay treatment initiation, limiting market expansion. To overcome these challenges and provide timely access to suitable medical treatments, increased awareness of arthritis symptoms and improved diagnostic skills are essential for driving the arthritic therapeutic market's growth.

The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. The North American region is both the leading and the fastest-growing region in the Arthritic Therapeutic Market. This dominance is primarily due to the high prevalence of arthritis and related conditions, coupled with a well-established healthcare infrastructure that supports advanced therapeutic treatments. The region boasts a high level of awareness about arthritis and its treatments among patients and healthcare providers, which drives demand for effective therapies. Additionally, North America is home to numerous leading pharmaceutical companies and research institutions that are at the forefront of developing innovative arthritis treatments. The availability of advanced diagnostic tools and a robust pipeline of new therapeutic agents further contribute to the region's market leadership. Factors such as favorable reimbursement policies, substantial healthcare spending, and ongoing investments in research and development also play a significant role in propelling the growth of the arthritic therapeutic market in North America.

Major market players included in this report are:
Viatris Inc.
Novartis AG
LEO Pharma
Bausch Health (Storz Ophthalmic Instrument)
Johnson & Johnson
Merck & Co., Inc.
AbbVie Inc.
Pfizer Inc.
Amgen Inc.
Celltrion Inc.
Roche Holding AG
Eli Lilly and Company
UCB S.A.
Bristol-Myers Squibb Company
Sanofi
The detailed segments and sub-segment of the market are explained below:
By Product Type:
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Disease Modified Anti-rheumatoid Drugs (DMARDs)
Biologics
Others
By Application:
Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Others
By Region:
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
South Africa
North Africa
Rest of MEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.